ImmunityBio’s findings showed that ANKTIVA plus BCG generated savings of up to $151,438 per cystectomy avoided over a three-year period in a U.S. Medicare population. ・The analysis also found lower ...

TAR-200 plus cetrelimab effective in reducing tumor size in those with muscle-invasive disease, potentially improving surgical outcomes and lowering risk of recurrence In the interim analysis of the ...

For people facing aggressive bladder cancer that no longer responds to standard treatment, options have often been grim—either undergo life-changing surgery to remove the bladder or try less effective ...

Investigational TAR-200 monotherapy demonstrates high complete response rate without the need for reinduction or additive therapy in patients who are Bacillus Calmette-Guérin (BCG)-unresponsive "The ...

The study is ongoing, and future analyses will include survival outcomes, researchers say. Adding TAR-200 to neoadjuvant treatment with cetrelimab can improve the pathologic complete response (pCR) ...

“Radical cystectomy is a life-changing operation with considerable morbidity and quality of life considerations,” said Joseph Jacob, MD, MS, presenting author and associate professor of urology at ...

TAR-200 demonstrated high DFS and bladder preservation rates in BCG-unresponsive, high-risk non-muscle-invasive bladder cancer with papillary-only disease. The phase 2b SunRISe-1 study showed over 80% ...

Patients with muscle-invasive bladder cancer who were treated with presurgical chemotherapy may have a 55% lower risk of death, research shows. Patients with muscle-invasive bladder cancer who are not ...

“The majority of patients remained free of cancer recurrence during this critical early study period, highlighting the potential of TAR-200 as a highly effective treatment for these patients who may ...

BEERSE, BELGIUM , Sept. 15, 2024 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a Johnson & Johnson company, today announced additional results from the pivotal Phase 2b SunRISe-1 study, ...